Putting chirality to work: The strategy of chiral switches

Israel Agranat; Hava Caner; John Caldwell

doi:10.1038/nrd915

Putting chirality to work: The strategy of chiral switches

Israel Agranat^*, Hava Caner, John Caldwell

^*Corresponding author for this work

Institute of Chemistry

Research output: Contribution to journal › Review article › peer-review

564 Scopus citations

Abstract

Most of the new drugs reaching the market today are single enantiomers, rather than the racemic mixtures that dominated up to ten years ago. Many of the new single-enantiomer drugs were developed as such, but there are also important examples of new single-enantiomer drugs derived from 'chiral switches' of established racemates. Indeed, a well-timed chiral switch can offer enhanced therapy and further profitability as a 'line extension' of a major racemic drug with patents that are expiring.

Original language	English
Pages (from-to)	753-768
Number of pages	16
Journal	Nature Reviews Drug Discovery
Volume	1
Issue number	10
DOIs	https://doi.org/10.1038/nrd915
State	Published - Oct 2002

Access to Document

10.1038/nrd915

Cite this

@article{7cf9a59866694ea0806b25d3f5e2c9ec,

title = "Putting chirality to work: The strategy of chiral switches",

abstract = "Most of the new drugs reaching the market today are single enantiomers, rather than the racemic mixtures that dominated up to ten years ago. Many of the new single-enantiomer drugs were developed as such, but there are also important examples of new single-enantiomer drugs derived from 'chiral switches' of established racemates. Indeed, a well-timed chiral switch can offer enhanced therapy and further profitability as a 'line extension' of a major racemic drug with patents that are expiring.",

author = "Israel Agranat and Hava Caner and John Caldwell",

year = "2002",

month = oct,

doi = "10.1038/nrd915",

language = "אנגלית",

volume = "1",

pages = "753--768",

journal = "Nature Reviews Drug Discovery",

issn = "1474-1776",

publisher = "Nature Research",

number = "10",

}

TY - JOUR

T1 - Putting chirality to work

T2 - The strategy of chiral switches

AU - Agranat, Israel

AU - Caner, Hava

AU - Caldwell, John

PY - 2002/10

Y1 - 2002/10

N2 - Most of the new drugs reaching the market today are single enantiomers, rather than the racemic mixtures that dominated up to ten years ago. Many of the new single-enantiomer drugs were developed as such, but there are also important examples of new single-enantiomer drugs derived from 'chiral switches' of established racemates. Indeed, a well-timed chiral switch can offer enhanced therapy and further profitability as a 'line extension' of a major racemic drug with patents that are expiring.

AB - Most of the new drugs reaching the market today are single enantiomers, rather than the racemic mixtures that dominated up to ten years ago. Many of the new single-enantiomer drugs were developed as such, but there are also important examples of new single-enantiomer drugs derived from 'chiral switches' of established racemates. Indeed, a well-timed chiral switch can offer enhanced therapy and further profitability as a 'line extension' of a major racemic drug with patents that are expiring.

UR - http://www.scopus.com/inward/record.url?scp=0036782116&partnerID=8YFLogxK

U2 - 10.1038/nrd915

DO - 10.1038/nrd915

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 12360254

AN - SCOPUS:0036782116

SN - 1474-1776

VL - 1

SP - 753

EP - 768

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

IS - 10

ER -

Putting chirality to work: The strategy of chiral switches

Abstract

Access to Document

Other files and links

Fingerprint

Cite this